Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announcement on Progress of Entrusted Wealth Management Using Idle Own Funds
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false records, misleading statements, or significant omissions.
I. Overview
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the 28th meeting of the 8th Board of Directors and the 28th meeting of the 8th Supervisory Board on October 30, 2025. The proposal "On Using Idle Own Funds for Entrusted Wealth Management" was deliberated and approved. The Company and its subsidiaries (subsidiaries included in the consolidated financial statements) are permitted to use no more than RMB 400,000,000 of idle own funds for entrusted wealth management, provided that daily production and operation and project construction fund needs are met and risks are effectively controlled. The term of this investment is twelve months from the date of approval by the Board of Directors. The transaction amount at any point within the term shall not exceed RMB 400,000,000. Within the aforementioned term and amount, funds can be used on a revolving basis. This investment matter will be authorized to the Chairman for implementation within the aforementioned limit.
The above details can be found in the relevant announcements published by the Company on October 31, 2025, in "Securities Times," "Shanghai Securities News," and on the Juchao Information Network (www.cninfo.com.cn).